Literature DB >> 19074870

Cancer stem cells are enriched in the side population cells in a mouse model of glioma.

Molly A Harris1, Hyuna Yang, Benjamin E Low, Joydeep Mukherjee, Joydeep Mukherje, Abhijit Guha, Roderick T Bronson, Leonard D Shultz, Mark A Israel, Kyuson Yun.   

Abstract

The recent identification of cancer stem cells (CSCs) in multiple human cancers provides a new inroad to understanding tumorigenesis at the cellular level. CSCs are defined by their characteristics of self-renewal, multipotentiality, and tumor initiation upon transplantation. By testing for these defining characteristics, we provide evidence for the existence of CSCs in a transgenic mouse model of glioma, S100beta-verbB;Trp53. In this glioma model, CSCs are enriched in the side population (SP) cells. These SP cells have enhanced tumor-initiating capacity, self-renewal, and multipotentiality compared with non-SP cells from the same tumors. Furthermore, gene expression analysis comparing fluorescence-activated cell sorting-sorted cancer SP cells to non-SP cancer cells and normal neural SP cells identified 45 candidate genes that are differentially expressed in glioma stem cells. We validated the expression of two genes from this list (S100a4 and S100a6) in primary mouse gliomas and human glioma samples. Analyses of xenografted human glioblastoma multiforme cell lines and primary human glioma tissues show that S100A4 and S100A6 are expressed in a small subset of cancer cells and that their abundance is positively correlated to tumor grade. In conclusion, this study shows that CSCs exist in a mouse glioma model, suggesting that this model can be used to study the molecular and cellular characteristics of CSCs in vivo and to further test the CSC hypothesis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19074870      PMCID: PMC2841432          DOI: 10.1158/0008-5472.CAN-08-0786

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  49 in total

1.  Genetic determinants of malignancy in a mouse model for oligodendroglioma.

Authors:  William A Weiss; Michael J Burns; Christopher Hackett; Ken Aldape; John R Hill; Hiroko Kuriyama; Nagato Kuriyama; Nadezhda Milshteyn; Tim Roberts; Michael F Wendland; Ron DePinho; Mark A Israel
Journal:  Cancer Res       Date:  2003-04-01       Impact factor: 12.701

2.  Expression of S100A6 and S100A4 in matched samples of human colorectal mucosa, primary colorectal adenocarcinomas and liver metastases.

Authors:  Keiko Komatsu; Kohei Murata; Masao Kameyama; Masako Ayaki; Mutsuko Mukai; Shingo Ishiguro; Jun Miyoshi; Masaharu Tatsuta; Masahiro Inoue; Hiroyuki Nakamura
Journal:  Oncology       Date:  2002       Impact factor: 2.935

3.  CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells.

Authors:  Jian Wang; Per Ø Sakariassen; Oleg Tsinkalovsky; Heike Immervoll; Stig Ove Bøe; Agnete Svendsen; Lars Prestegarden; Gro Røsland; Frits Thorsen; Linda Stuhr; Anders Molven; Rolf Bjerkvig; Per Ø Enger
Journal:  Int J Cancer       Date:  2008-02-15       Impact factor: 7.396

4.  Isolation and molecular characterization of cancer stem cells in MMTV-Wnt-1 murine breast tumors.

Authors:  Robert W Cho; Xinhao Wang; Maximilian Diehn; Kerby Shedden; Grace Y Chen; Gavin Sherlock; Austin Gurney; John Lewicki; Michael F Clarke
Journal:  Stem Cells       Date:  2007-11-01       Impact factor: 6.277

5.  Mesenchyme Forkhead 1 (FOXC2) plays a key role in metastasis and is associated with aggressive basal-like breast cancers.

Authors:  Sendurai A Mani; Jing Yang; Mary Brooks; Gunda Schwaninger; Alicia Zhou; Naoyuki Miura; Jeffery L Kutok; Kimberly Hartwell; Andrea L Richardson; Robert A Weinberg
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-30       Impact factor: 11.205

6.  Cancer stem cells in radiation resistance.

Authors:  Jeremy N Rich
Journal:  Cancer Res       Date:  2007-10-01       Impact factor: 12.701

7.  Tumor growth need not be driven by rare cancer stem cells.

Authors:  Priscilla N Kelly; Aleksandar Dakic; Jerry M Adams; Stephen L Nutt; Andreas Strasser
Journal:  Science       Date:  2007-07-20       Impact factor: 47.728

8.  S100A6 is increased in a stepwise manner during pancreatic carcinogenesis: clinical value of expression analysis in 98 pancreatic juice samples.

Authors:  Kenoki Ohuchida; Kazuhiro Mizumoto; Jun Yu; Hiroshi Yamaguchi; Hiroyuki Konomi; Eishi Nagai; Koji Yamaguchi; Masazumi Tsuneyoshi; Masao Tanaka
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-04       Impact factor: 4.254

9.  Phenotypic characterization of human colorectal cancer stem cells.

Authors:  Piero Dalerba; Scott J Dylla; In-Kyung Park; Rui Liu; Xinhao Wang; Robert W Cho; Timothy Hoey; Austin Gurney; Emina H Huang; Diane M Simeone; Andrew A Shelton; Giorgio Parmiani; Chiara Castelli; Michael F Clarke
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-04       Impact factor: 11.205

10.  Increased expression of S100A6 at the invading fronts of the primary lesion and liver metastasis in patients with colorectal adenocarcinoma.

Authors:  K Komatsu; Y Kobune-Fujiwara; A Andoh; S Ishiguro; H Hunai; N Suzuki; M Kameyama; K Murata; J Miyoshi; H Akedo; M Tatsuta; H Nakamura
Journal:  Br J Cancer       Date:  2000-09       Impact factor: 7.640

View more
  71 in total

1.  Localization of CD44 and CD90 positive cells to the invasive front of breast tumors.

Authors:  Vera S Donnenberg; Albert D Donnenberg; Ludovic Zimmerlin; Rodney J Landreneau; Rohit Bhargava; Ryan A Wetzel; Per Basse; Adam M Brufsky
Journal:  Cytometry B Clin Cytom       Date:  2010-04-30       Impact factor: 3.058

2.  Cancer cells cyclically lose and regain drug-resistant highly tumorigenic features characteristic of a cancer stem-like phenotype.

Authors:  Kaijie He; Tong Xu; Amir Goldkorn
Journal:  Mol Cancer Ther       Date:  2011-04-25       Impact factor: 6.261

Review 3.  Cancer stem cells: a new framework for the design of tumor therapies.

Authors:  Boyan K Garvalov; Till Acker
Journal:  J Mol Med (Berl)       Date:  2010-10-02       Impact factor: 4.599

4.  Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival.

Authors:  Ines A Silva; Shoumei Bai; Karen McLean; Kun Yang; Kent Griffith; Dafydd Thomas; Christophe Ginestier; Carolyn Johnston; Angela Kueck; R Kevin Reynolds; Max S Wicha; Ronald J Buckanovich
Journal:  Cancer Res       Date:  2011-04-15       Impact factor: 12.701

5.  SYK inhibition blocks proliferation and migration of glioma cells and modifies the tumor microenvironment.

Authors:  Gerald Moncayo; Michal Grzmil; Tatiana Smirnova; Pawel Zmarz; Roland M Huber; Debby Hynx; Hubertus Kohler; Yuhua Wang; Hans-Rudolf Hotz; Nancy E Hynes; Georg Keller; Stephan Frank; Adrian Merlo; Brian A Hemmings
Journal:  Neuro Oncol       Date:  2018-04-09       Impact factor: 12.300

6.  Harnessing the DNA Dye-triggered Side Population Phenotype to Detect and Purify Cancer Stem Cells from Biological Samples.

Authors:  Maximilian Boesch; Elisabeth Hoflehner; Dominik Wolf; Guenther Gastl; Sieghart Sopper
Journal:  J Vis Exp       Date:  2017-05-10       Impact factor: 1.355

Review 7.  Glioblastoma stem cells: Molecular characteristics and therapeutic implications.

Authors:  Nermin Sumru Bayin; Aram Sandaldjian Modrek; Dimitris George Placantonakis
Journal:  World J Stem Cells       Date:  2014-04-26       Impact factor: 5.326

8.  "The development tumor model" to study and monitor the entire progression of both primary and metastatic tumors.

Authors:  Enrico Brognaro
Journal:  Tumour Biol       Date:  2013-11-10

9.  Expression and function of ABCG2 and XIAP in glioblastomas.

Authors:  Ivette F Emery; Archana Gopalan; Stephanie Wood; Kin-Hoe Chow; Chiara Battelli; Joshy George; Hagen Blaszyk; Jeffrey Florman; Kyuson Yun
Journal:  J Neurooncol       Date:  2017-04-21       Impact factor: 4.130

Review 10.  Tumor initiating cells in malignant gliomas: biology and implications for therapy.

Authors:  Costas G Hadjipanayis; Erwin G Van Meir
Journal:  J Mol Med (Berl)       Date:  2009-02-03       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.